Which companies are Thalys Medical Technology's closest peers?

The cockpit's peer set: Shanghai Lily & Beauty Cosmetics (605136.SS), Shenzhen Neptunus Bioengineering (000078.SZ), Arata (2733.T), GKHT Medical Technology (301370.SZ), Vital KSK (3151.T), Excelsior Medical (4104.TW), Shanghai New World (600628.SS), Gongwin Biopharm (6617.TWO).

Is Thalys Medical Technology expensive compared with its peers?

On ev / sales it trades at 4.1× against a peer median of 1.2×, 4th most expensive of 21 in its peer set.

How has Thalys Medical Technology stock performed?

Over six months to 6 Nov 2026 the shares returned -29.2% against -5.6% for the median peer; over one year -38.0%.

← CockpitCompetitor Analysis › 603716.SS Thalys Medical Technology Group Inc. Class AOpen in the cockpit ↗

Thalys Medical Technology Group Inc. Class A603716.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Distributors

Momentum neutral 42

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$501M

US dollars, full cap

Free float

89%

of shares outstanding

$/day

$29.4M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-16.6 pp

WACC 7.2%

Hurdle

n/a

no reverse DCF

Close · CNYCN¥15.06

1D-3.8%

1W-9.2%

1M-6.9%

3M-6.4%

6M-29.2%

YTD-26.7%

1Y-38.0%

ATR %6.1%

52w lowhigh52.7% off high

What Thalys Medical Technology does

Employees: 1,045

Thalys Medical Technology at a glance

Size Thalys Medical Technology (603716.SS) is a China Health Care company (Medical Distributors) with a market value of $501M, the 3866th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥15.06 on 6 Nov 2026.

Performance Over six months the shares fell 29.2%, against -5.6% for the median peer and -16.4% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue fell 41.0% over the last twelve months (peer median +2.5%); the operating margin is -16.8% (peer median 1.6%).

Valuation It trades at 4.1× enterprise value to sales against a peer median of 1.2× (4th most expensive of 21).

Capital Return on invested capital runs 16.6 points below its cost of capital (7.2% WACC).

Relative performance

Six months, rebased to 100: Thalys Medical Technology against the median of its 20 peers (local-currency closes).

Thalys Medical Technology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥836M	CN¥1.07B	CN¥1.80B	CN¥2.00B	CN¥2.30B
Revenue growth	—	-41%	-10%	-13%	—
Gross profit	CN¥172M	CN¥224M	CN¥310M	CN¥363M	CN¥433M
EBITDA	-CN¥95.4M	-CN¥20.5M	CN¥65.8M	CN¥12.0M	CN¥91.3M
Net income	-CN¥199M	-CN¥207M	-CN¥209M	-CN¥159M	-CN¥154M
Free cash flow	CN¥3.79M	-CN¥43.5M	CN¥76.4M	CN¥96.6M	-CN¥25.6M
Capital expenditure	CN¥2.84M	CN¥5.72M	CN¥23.2M	CN¥40.8M	CN¥54.6M
Total debt	CN¥259M	CN¥457M	CN¥940M	CN¥1.06B	CN¥1.45B

Quarterly statements and history in the cockpit →

Thalys Medical Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Thalys Medical Technology is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Thalys Medical Technology is the large dot.

Thalys Medical Technology competitors and peer comparison

How Thalys Medical Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Thalys Medical Technology against its 20 peers (data as of 6 Nov 2026)
Measure	603716.SS	Peer median	Rank in peer set
1-month return	-6.9%	-0.8%	7th lowest of 21
6-month return	-29.2%	-5.6%	2nd lowest of 21
Distance from 52-week high	-52.7%	-20.4%	3rd lowest of 21
Revenue growth (TTM)	-41.0%	+2.5%	lowest of 21
Operating margin	-16.8%	1.6%	3rd lowest of 21
EV / Sales	4.1×	1.2×	4th most expensive of 21
ROIC minus cost of capital	-16.6 pp	-2.0 pp	4th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Thalys Medical Technology 603716.SS	China	$501M	-29%	-41%	-17%	4.1×	n/a	n/a
Shanghai Lily & Beauty Cosmetics 605136.SS	China	$517M	-21%	+10%	0%	1.2×	12.2%	-18.1%
Shenzhen Neptunus Bioengineering 000078.SZ	China	$475M	-60%	-22%	-1%	0.6×	59.0%	-7.8%
Arata 2733.T	Japan	$552M	-7%	+3%	1%	0.1×	-7.1%	+3.8%
GKHT Medical Technology 301370.SZ	China	$569M	-22%	-11%	1%	0.8×	14.4%	+7.5%
Vital KSK 3151.T	Japan	$428M	+7%	+2%	1%	0.1×	0.4%	+2.6%
Excelsior Medical 4104.TW	Taiwan	$409M	+1%	+6%	8%	1.6×	2.9%	+5.7%
Shanghai New World 600628.SS	China	$623M	-11%	-2%	6%	2.4×	0.3%	+1.0%
Gongwin Biopharm 6617.TWO	Taiwan	$388M	+50%	+22%	-571%	267.5×	n/a	n/a
Shanghai Universal Biotech 301166.SZ	China	$376M	-6%	+15%	-4%	1.2×	n/a	n/a
Rongfeng 000668.SZ	China	$327M	-5%	+61%	14%	5.3×	11.4%	+30.0%
Medios ILM1.DE	Germany	$324M	-9%	+10%	2%	0.2×	-1.3%	+27.1%
Goodwill E-Health Info 688246.SS	China	$323M	-25%	-30%	-68%	6.4×	n/a	n/a
Nagaileben 7447.T	Japan	$319M	-1%	+1%	22%	1.6×	n/a	n/a
Neuca NEU.WA	Poland	$817M	-1%	+8%	2%	0.3×	5.0%	+8.1%
Shanghai Pioneer 1345.HK	Hong Kong	$300M	-18%	-6%	11%	1.7×	-6.7%	-1.4%
Entero Healthcare Solutions ENTERO.NS	India	$875M	+50%	+32%	4%	1.2×	21.8%	+29.9%
Shanghai Haohai Biological Technology 6826.HK	Hong Kong	$926M	-27%	-5%	-2%	2.0×	17.2%	+12.4%
Guangxi LiuYao 603368.SS	China	$994M	+2%	+2%	5%	0.4×	-9.5%	+6.0%
Arjo ARJO-B.ST	Sweden	$1.02B	+48%	0%	8%	1.3×	-1.3%	+3.9%
DocMorris DOCM.SW	Switzerland	$1.02B	+136%	+11%	-8%	0.9×	n/a	n/a

Questions

Which companies are Thalys Medical Technology's closest peers?: The cockpit's peer set: Shanghai Lily & Beauty Cosmetics (605136.SS), Shenzhen Neptunus Bioengineering (000078.SZ), Arata (2733.T), GKHT Medical Technology (301370.SZ), Vital KSK (3151.T), Excelsior Medical (4104.TW), Shanghai New World (600628.SS), Gongwin Biopharm (6617.TWO).
Is Thalys Medical Technology expensive compared with its peers?: On ev / sales it trades at 4.1× against a peer median of 1.2×, 4th most expensive of 21 in its peer set.
How has Thalys Medical Technology stock performed?: Over six months to 6 Nov 2026 the shares returned -29.2% against -5.6% for the median peer; over one year -38.0%.